Ramotowski, Bogumił http://orcid.org/0000-0001-7267-2621
Undas, Anetta http://orcid.org/0000-0002-0667-8109
Budaj, Andrzej http://orcid.org/0000-0002-6395-2098
Funding for this research was provided by:
Centre of Postgraduate Medical Education (501–1–10–14–20/21)
Article History
Accepted: 14 April 2023
First Online: 4 May 2023
Declarations
:
: Dr. Ramotowski reports honoraria for lectures from Werfen, GE, Boerhinger Ingelheim. Prof. Undas: none. Prof. Budaj reports consulting fees from Sanofi-Aventis, AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, investigator fees from Sanofi-Aventis, AstraZeneca, GlaxoSmithKline, Novartis, Bristol-Myers Squibb/Pfizer, Eisai, Bayer, NovoNordisk and Amgen; honoraria for lectures from Sanofi-Aventis, AstraZeneca, Bristol-Myers Squibb/Pfizer, Novartis and Bayer.
: The study complied with the principles of the Declaration of Helsinki. Approval numbers 16/PB/2014 and 10/PB-A/2015 were provided by the Ethics Committee of the Centre of Postgraduate Medical Education. Informed consent was obtained from all patients. The study was retrospectively registered at ClinicalTrials.gov on the 3rd of March 2021 with a NCT040784702 trial identifier under protocol ID 16/PB/2014 as part of a larger project.